Vor Biopharma (VOR) risk factors, FY2025 10-K

Vor Biopharma's FY2025 10-K, filed Mar 30, 2026, lists 85 risk factors in 8 groups. Against the prior year's 97: 16 new, 28 dropped, 26 substantially reworded.

Open VOR in Gloom →
Vor Biopharma's chart, financials and news, free in your browser.Open VOR in Gloom →
Risk factors listed
858 groups
New this year
16vs 97 last year
Dropped
28since the prior 10-K
Substantially reworded
26of those kept
Section length
35k wordsItem 1A

What the changes say

  • Vor Biopharma expanded its portfolio by in-licensing telitacicept from RemeGen, creating new operational and regulatory dependencies on third-party trials in China.

What changed since the prior 10-K

New

  • NewRisks Related to Development, Manufacturing and Commercialization

    We may derive results and data for telitacicept from clinical trials conducted by RemeGen in China; our access to the clinical results and data may be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA, or other comparable regulatory authorities

    We rely on RemeGen's clinical trials for telitacicept in China, which are outside our control and may not be accepted by the FDA.

  • NewRisks Related to Development, Manufacturing and Commercialization

    We are dependent on third parties accurately generating and reporting data related to our product candidates, and their conduct could adversely affect our business

    We depend on third parties like RemeGen to accurately generate and report preclinical and clinical data for in-licensed product candidates.

  • NewRisks Related to Development, Manufacturing and Commercialization

    studies, create negative market perception affecting future commercial potential, impact our ability to pursue strategic alternatives for such product candidates, or result in increased regulatory scrutiny across our programs

    Clinical trials for our product candidates may fail, show unacceptable side effects, or face regulatory suspension and increased scrutiny.

  • NewRisks Related to Development, Manufacturing and Commercialization

    Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more subject data become available and are subject to audit and verification procedures that could result in material changes in the final data

    Interim and topline clinical data we publish may change after full evaluation and mandatory audit and verification procedures.

  • NewRisks Related to Development, Manufacturing and Commercialization

    interim, topline or preliminary data by us or by our competitors could result in volatility in the price of our common stock

    Public disclosure of interim data or differing interpretations by regulators and competitors could cause volatility in our common stock price.

  • NewRisks Related to Development, Manufacturing and Commercialization

    Negative developments in the field of protein-based therapies, including in particular fusion protein therapies, or approved therapies or therapies in development for the treatment of B cell-mediated autoimmune diseases, could damage public perception of our product candidate and negatively affect our business

    Negative developments or adverse events in fusion protein therapies or B cell-mediated autoimmune treatments could damage public perception of telitacicept.

  • NewRisks Related to Development, Manufacturing and Commercialization

    Fusion protein therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of telitacicept or other product candidates or otherwise harm our business

    Fusion proteins like telitacicept are technically complex to manufacture, risking supply delays and high production costs.

  • NewRisks Related to Regulatory Review

    changes in the standard of care treatment guidelines

    Changes in standard of care treatment guidelines could require additional clinical testing or result in narrower marketing approval.

  • NewRisks Related to Regulatory Review

    Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize telitacicept or any other product candidate we may develop in the United States or any other jurisdiction, and any such approval may be for a more narrow indication than we seek

    We cannot predict if or when telitacicept will gain regulatory approval in the US or elsewhere, and approvals may be for narrow indications.

  • NewRisks Related to Regulatory Review

    If we experience significant delays or difficulties in the enrollment or retention of patients in clinical trials, the cost of developing product candidates could increase and our receipt of necessary regulatory approvals could be delayed or prevented

    Difficulties in patient enrollment and retention could increase development costs and delay regulatory approvals for our product candidates.

  • NewRisks Related to Regulatory Review

    changes in standard of care treatment guidelines

    Significant clinical trial enrollment delays may force us to delay, limit, or terminate ongoing studies.

  • NewRisks Related to Our Intellectual Property

    territories other than Greater China, with the right to grant sublicenses, and a non-exclusive license to manufacture the telitacicept worldwide for use in the licensed territory

    Termination of our license agreement with RemeGen would result in the loss of rights to develop and commercialize telitacicept.

  • NewRisks Related to Our Intellectual Property

    infringement for uses of patented technology reasonably related to the development and submission of information under a federal law which regulates the manufacture, use, or sale of drugs

  • NewRisks Related to Regulatory and Other Legal Compliance Matters

    and Medicaid, imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects

  • NewRisks Related to Regulatory and Other Legal Compliance Matters

    Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program

  • NewRisks Related to Regulatory and Other Legal Compliance Matters

    coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely

Dropped

  • DroppedRisks Related to Our Financial Position and Need for Additional Capital

    There is substantial doubt regarding our ability to continue as a going concern

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    eHSCs is an emerging technology containing risk and might never lead to commercially viable products

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    establishing sales and marketing capabilities ahead of and after obtaining any regulatory approval to gain market acceptance, and obtaining coverage, adequate reimbursement and pricing by third-party payors and governmental healthcare programs

    Substantial doubt regarding our ability to continue as a going concern with cash of $91.9 million.

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    We may not be successful in our efforts to identify, develop and commercialize additional product candidates. If these efforts are unsuccessful, we may never become a commercial stage company or generate any revenues

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    our reputation may suffer

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    We are in the early stages of testing some of our product candidates in clinical trials and any favorable preclinical results are not predictive of results that may be observed in clinical trials

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    of product development. Any such adverse events may cause us to delay, limit or terminate planned clinical trials, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    Development of a product candidate such as trem-cel, which is intended for use in combination or in sequence with an already approved therapy, will present increased complexity and more or different challenges than development of a product candidate for use as a single agent

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    If we are unable to successfully develop our current programs into a comprehensive portfolio of product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our current and future product candidates

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    Adverse public perception of genetic medicines, and of genome engineering in particular, including as a result of other trials out of our control, such as the VCAR33AUTO trial currently sponsored by NMDP, may negatively impact regulatory approval of, and/or demand for, our potential products

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    neither experimental nor investigational

    Risks related to developing trem-cel and other unproven eHSCs as an emerging technology.

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical products, will apply to companion diagnostics

    Establishing sales capabilities and obtaining third-party reimbursement for trem-cel in AML.

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    Insurance coverage is also increasingly expensive and we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements

    Unsuccessful efforts to identify and develop additional product candidates beyond trem-cel and VCAR33.

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    The process for treating cancer patients using T cell therapy or other cell-based targeted therapies is subject to human and systemic risks

    Potential damage to company reputation from failing to achieve market acceptance.

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    Prior treatments can alter the cancer and negatively impact chances for achieving clinical activity with our CAR-T or other cell-based targeted therapies

    Early stage of clinical testing and high failure rates despite favorable preclinical results.

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    We and any third-party manufacturers and any third-party collaborators may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing such product candidates and commercializing approved products, if any

    Preclinical and preliminary clinical results not predicting later stage outcomes.

  • DroppedRisks Related to Discovery, Development, Manufacturing and Commercialization

    We have not yet developed a validated methodology for freezing and thawing large quantities of eHSCs or of VCAR33, which we believe will be required for the storage and distribution of our product candidates, and we may face additional logistical challenges in the distribution of our product candidates

    Increased complexity of developing trem-cel in combination or sequence with approved therapies.

  • DroppedRisks Related to Regulatory Review

    disruption in the supply or availability of Mylotarg or any future targeted therapeutics we use with our eHSCs

    Failure to develop current programs into a comprehensive portfolio of product candidates.

  • DroppedRisks Related to Regulatory Review

    the field of genome engineering is subject to a number of intellectual property disputes

  • DroppedRisks Related to Regulatory Review

    changes to diagnostic technologies, methodologies or criteria used to identify HCT patients at high risk for relapse

  • DroppedRisks Related to Regulatory Review

    If we are unable to successfully identify patients who are likely to benefit from our product candidates or eligible donors, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates

  • DroppedRisks Related to Regulatory Review

    we may not realize the full commercial potential of any product candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from administration of our genetically engineered cells

  • DroppedRisks Related to Our Relationships with Third Parties

    site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our product candidates

    Adverse public perception of genetic medicines and genome engineering like the VCAR33AUTO trial.

  • DroppedRisks Related to Our Intellectual Property

    in-licensed, though similar risks would apply to any patents or patent applications that we now own or may own or in-license in the future

    Uncertainty related to third-party coverage and Medicare reimbursement for eHSCs.

  • DroppedRisks Related to Our Intellectual Property

    the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized

    International price controls and cost-containment initiatives for biological products and companion diagnostics.

  • DroppedRisks Related to Regulatory and Other Legal Compliance Matters

    transparency, health data privacy, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research as well as market, sell and distribute our products for which we obtain marketing approval

Reworded

  • 100% rewrittenRisks Related to Our Intellectual Property

    We are highly dependent on intellectual property licensed from third parties and termination of these licenses could result in the loss of significant rights, which would harm our business

    Replaced Columbia University license details with the June 2025 RemeGen license agreement for telitacicept.

    Was: We are highly dependent on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business

  • 91% rewrittenRisks Related to Our Intellectual Property

    The patent protection we obtain for our product candidates may not be sufficient to provide us with any competitive advantage or our patents may be challenged

    Retained patent challenge risks while adjusting formatting without altering core liability terms.

  • 88% rewrittenRisks Related to Regulatory Review

    experience damage to our reputation

    Maintained reputation damage risk regarding clinical trial delays without substantive changes to terms.

  • 83% rewrittenRisks Related to Regulatory and Other Legal Compliance Matters

    Healthcare and other reform legislation, may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize our product candidates, if approved, and affect the prices we, or they, may obtain

    Preserved healthcare reform legislation risks affecting commercial pricing and product approval difficulty.

  • 78% rewrittenRisks Related to Our Intellectual Property

    We may not be successful in acquiring or in-licensing necessary rights to key technologies underlying our product candidates

    Updated in-licensing dependency to explicitly include RemeGen alongside previous licensors like Columbia and NCI.

  • 72% rewrittenRisks Related to Development, Manufacturing and Commercialization

    Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials, particularly for clinical trials that involve only a small number of patients

    Added specific warning that RemeGen's prior preclinical success and Chinese approvals do not guarantee future trial success for us.

    Was: Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials, particularly for our clinical trials that involve only a small number of patients

  • 64% rewrittenRisks Related to the Ownership of Our Common Stock

    An active trading market for our common stock may not be sustained

    Removed mention of Nasdaq listing date from February 2021 while keeping trading market sustainability risks.

  • 60% rewrittenRisks Related to Our Relationships with Third Parties

    form relationships with other entities, some of which may be our competitors

    Narrowed third-party risk scope specifically to clinical trials rather than preclinical studies.

  • 55% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

    We have incurred significant net losses since inception. We expect to incur net losses for the foreseeable future and may never achieve or maintain profitability

  • 52% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

    Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates

  • 49% rewrittenRisks Related to Development, Manufacturing and Commercialization

    We are substantially dependent on the success of our lead product candidate, telitacicept. If we are unable to complete development of, obtain approval for and commercialize telitacicept in a timely manner, our business will be harmed

    Was: We are substantially dependent on the success of our two most advanced product candidates, trem-cel and VCAR33. If we are unable to complete development of, obtain approval for and commercialize trem-cel or VCAR33 in a timely manner, our business will be harmed

  • 49% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

    We have a limited operating history, have not yet completed any clinical trials and have no history of commercializing products, which may make it difficult to evaluate the success of our business to date and to assess our future viability

  • 39% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

    We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts

  • 37% rewrittenRisks Related to Regulatory and Other Legal Compliance Matters

    Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs

  • 34% rewrittenRisks Related to the Ownership of Our Common Stock

    A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well

  • 33% rewrittenRisks Related to the Ownership of Our Common Stock

    The market price of our common stock may be volatile

  • 32% rewrittenRisks Related to Development, Manufacturing and Commercialization

    unforeseen costs and expenses associated with creating an independent commercialization organization

  • 29% rewrittenRisks Related to Regulatory and Other Legal Compliance Matters

    injunctions or the imposition of civil or criminal penalties

  • 27% rewrittenRisks Related to Development, Manufacturing and Commercialization

    our ability to compete with other treatments

  • 27% rewrittenRisks Related to Our Intellectual Property

    countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates

  • 26% rewrittenRisks Related to Development, Manufacturing and Commercialization

    We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success

  • 26% rewrittenRisks Related to the Ownership of Our Common Stock

    Unfavorable global economic conditions, new tariffs or bank closures could adversely affect our business, financial condition or results of operations

  • 25% rewrittenRisks Related to Development, Manufacturing and Commercialization

    If we or any contract manufacturers and suppliers that we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

  • 24% rewrittenRisks Related to Our Relationships with Third Parties

    reliance on the third party for regulatory compliance, quality assurance, safety and pharmacovigilance and related reporting

  • 24% rewrittenRisks Related to Employee Matters, Managing Growth and Information Technology

    Our insurance policies may be inadequate and potentially expose us to unrecoverable risks

  • 22% rewrittenRisks Related to Our Intellectual Property

    Third-party claims of intellectual property infringement, misappropriation or other violations may prevent or delay our product discovery and development efforts and have a material adverse effect on our business

All 85 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Position and Need for Additional Capital

  1. 01We have incurred significant net losses since inception. We expect to incur net losses for the foreseeable future and may never achieve or maintain profitability55% rewritten
  2. 02operate as a public company
  3. 03We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts39% rewritten
  4. 04the costs of operating as a public company
  5. 05Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates52% rewritten
  6. 06We have a limited operating history, have not yet completed any clinical trials and have no history of commercializing products, which may make it difficult to evaluate the success of our business to date and to assess our future viability49% rewritten
  7. 07We have never generated revenue from product sales and may never become profitable
  8. 08attract, hire and retain qualified personnel
  9. 09Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited

Risks Related to Development, Manufacturing and Commercialization

  1. 10We are substantially dependent on the success of our lead product candidate, telitacicept. If we are unable to complete development of, obtain approval for and commercialize telitacicept in a timely manner, our business will be harmed49% rewritten
  2. 11our ability to compete with other treatments27% rewritten
  3. 12We may derive results and data for telitacicept from clinical trials conducted by RemeGen in China; our access to the clinical results and data may be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA, or other comparable regulatory authoritiesNew
  4. 13We are dependent on third parties accurately generating and reporting data related to our product candidates, and their conduct could adversely affect our businessNew
  5. 14studies, create negative market perception affecting future commercial potential, impact our ability to pursue strategic alternatives for such product candidates, or result in increased regulatory scrutiny across our programsNew
  6. 15Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more subject data become available and are subject to audit and verification procedures that could result in material changes in the final dataNew
  7. 16interim, topline or preliminary data by us or by our competitors could result in volatility in the price of our common stockNew
  8. 17Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials, particularly for clinical trials that involve only a small number of patients72% rewritten
  9. 18We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success26% rewritten
  10. 19Even if a product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success
  11. 20If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing those product candidates if and when they are approved
  12. 21unforeseen costs and expenses associated with creating an independent commercialization organization32% rewritten
  13. 22Negative developments in the field of protein-based therapies, including in particular fusion protein therapies, or approved therapies or therapies in development for the treatment of B cell-mediated autoimmune diseases, could damage public perception of our product candidate and negatively affect our businessNew
  14. 23If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
  15. 24Fusion protein therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of telitacicept or other product candidates or otherwise harm our businessNew
  16. 25If we or any contract manufacturers and suppliers that we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business25% rewritten

Risks Related to Regulatory Review

  1. 26Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates
  2. 27changes in the standard of care treatment guidelinesNew
  3. 28experience damage to our reputation88% rewritten
  4. 29Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize telitacicept or any other product candidate we may develop in the United States or any other jurisdiction, and any such approval may be for a more narrow indication than we seekNew
  5. 30If we experience significant delays or difficulties in the enrollment or retention of patients in clinical trials, the cost of developing product candidates could increase and our receipt of necessary regulatory approvals could be delayed or preventedNew
  6. 31changes in standard of care treatment guidelinesNew

Risks Related to Our Relationships with Third Parties

  1. 32We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing
  2. 33form relationships with other entities, some of which may be our competitors60% rewritten
  3. 34reliance on the third party for regulatory compliance, quality assurance, safety and pharmacovigilance and related reporting24% rewritten
  4. 35We have and may enter into collaborations with third parties for the research, development and commercialization of our product candidates. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates
  5. 36Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations
  6. 37Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing
  7. 38Collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation
  8. 39Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates
  9. 40If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans

Risks Related to Our Intellectual Property

  1. 41We are highly dependent on intellectual property licensed from third parties and termination of these licenses could result in the loss of significant rights, which would harm our business100% rewritten
  2. 42territories other than Greater China, with the right to grant sublicenses, and a non-exclusive license to manufacture the telitacicept worldwide for use in the licensed territoryNew
  3. 43The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement
  4. 44Our commercial success depends on our ability to obtain, maintain and protect our intellectual property and proprietary technology
  5. 45countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates27% rewritten
  6. 46The patent protection we obtain for our product candidates may not be sufficient to provide us with any competitive advantage or our patents may be challenged91% rewritten
  7. 47If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed
  8. 48We may not be successful in acquiring or in-licensing necessary rights to key technologies underlying our product candidates78% rewritten
  9. 49infringement for uses of patented technology reasonably related to the development and submission of information under a federal law which regulates the manufacture, use, or sale of drugsNew
  10. 50Third-party claims of intellectual property infringement, misappropriation or other violations may prevent or delay our product discovery and development efforts and have a material adverse effect on our business22% rewritten
  11. 51Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
  12. 52We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
  13. 53Changes to patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
  14. 54We may not be able to protect our intellectual property rights throughout the world
  15. 55Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
  16. 56If we do not obtain patent term extension and data exclusivity for patents related to any of our product candidates, our business may be materially harmed
  17. 57Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets
  18. 58If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
  19. 59Intellectual property rights do not necessarily address all potential threats

Risks Related to Regulatory and Other Legal Compliance Matters

  1. 60Failure to obtain marketing approval in foreign jurisdictions would prevent product candidates from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue
  2. 61injunctions or the imposition of civil or criminal penalties29% rewritten
  3. 62and Medicaid, imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospectsNew
  4. 63Healthcare and other reform legislation, may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize our product candidates, if approved, and affect the prices we, or they, may obtain83% rewritten
  5. 64Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation ProgramNew
  6. 65coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likelyNew
  7. 66Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
  8. 67Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs37% rewritten

Risks Related to Employee Matters, Managing Growth and Information Technology

  1. 68Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified personnel
  2. 69We expect to expand our development, regulatory and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
  3. 70Our insurance policies may be inadequate and potentially expose us to unrecoverable risks24% rewritten

Risks Related to the Ownership of Our Common Stock

  1. 71An active trading market for our common stock may not be sustained64% rewritten
  2. 72The market price of our common stock may be volatile33% rewritten
  3. 73the other factors described in this “Risk Factors” section
  4. 74If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
  5. 75A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well34% rewritten
  6. 76Insiders have substantial control over our company, which could limit the ability of our other stockholders to affect the outcome of key transactions, including a change of control
  7. 77If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed
  8. 78We are an “emerging growth company” and a “smaller reporting company,” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
  9. 79We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
  10. 80Our management team has broad discretion in the use of our cash reserves and may not use them effectively
  11. 81We do not expect to pay any dividends for the foreseeable future. Accordingly our stockholders must rely on capital appreciation, if any, for any return on their investment
  12. 82Unfavorable global economic conditions, new tariffs or bank closures could adversely affect our business, financial condition or results of operations26% rewritten
  13. 83Provisions in our certificate of incorporation and bylaws and under Delaware law could make a change in control of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
  14. 84require the approval of the holders of at least 66 2 ⁄ 3 % of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws
  15. 85any action asserting a claim against us that is governed by the internal-affairs doctrine

Other Vor Biopharma 10-Ks

  • FY2024 10-K risk factors
    97 risks

    Vor Biopharma faces significant net losses, an accumulated deficit of $457.0 million, and substantial doubt about its going concern status.

    Filed Mar 20, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.